MINI FUTURE LONG - GILEAD SCIENCES | Delayed Deutsche Boerse AG 06:20:35 24/06/2024 pm IST | ||
| 1.71 EUR | +0.59% |
|
| Current month | +61.90% | ||
| 1 month | +25.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 1.71 | +0.59% |
| 21/24/21 | 1.7 | +14.09% |
| 20/24/20 | 1.49 | +55.21% |
| 19/24/19 | 0.96 | -2.04% |
| 18/24/18 | 0.98 | -12.50% |
Delayed Quote Deutsche Boerse AG
Last update June 24, 2024 at 06:20 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PN1URB |
| ISIN | DE000PN1URB3 |
| Date issued | 31/07/2020 |
| Strike | 52.63 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.84 € |
|---|---|
| Lowest since issue | 0.7 € |
| Spread | 0.03 € |
| Spread % | 1.73% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
70.67
USD
Average target price
82.89
USD
Spread / Average Target
+17.29%
- Stock Market
- Certificates
- Certificat
